Co-hosts Jörn Schattenberg and Roger Green review the 2023 Liver Forum with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. In this conversation, the group revisits a perspective-shifting session titled “A New Look at Statistics.”
Co-hosts Jörn Schattenberg and Roger Green review Liver Forum 14 with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. For this conversation, each panelist picks a session that captured their interest and Mazen provides a flavor of his talk on Compensated Cirrhosis Risk Stratification.
Co-hosts Jörn Schattenberg and Roger Green review Liver Forum 14 with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. In this conversation, Veronica recaps the aims of the Forum and each panelist shares their initial reactions around what makes the meeting special.
Co-hosts Jörn Schattenberg and Roger Green review the 2023 Liver Forum with Executive Director Veronica Miller. Joining the session are meeting speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. The group highlights how the event embodies truly integrative thinking.
Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this final conversation, the group share their interests around what’s to come for the second quarter in Fatty Liver.
Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, the group share thoughts around drug development and the possibility of new Phase 3 press releases on the imminent horizon. Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, the group share thoughts around drug development and the possibility of new Phase 3 press releases on the imminent horizon.
Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, the group discuss NICE and FibroScan in the primary care setting, frontline screening to enable early detection and prevent cirrhosis, the upcoming EASL Congress and more.
Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, Jörn describes his attendance at the 3rd Annual Liver Connect Conference in California.
This week, co-hosts Jörn Schattenberg, Louise Campbell and Roger Green discuss the 3rd Annual Liver Connect Conference, NICE approval process for FibroScan in primary care, updates in the therapeutic pipeline, pathways and the Surfing NASH 4th anniversary special. The session is fun and full of surprises – like a new metaphor from Roger to describe fatty liver disease.
In this episode of the Rising Tide series, co-hosts Ken Cusi and Roger Green are joined by KOL in public health, Jeff Lazarus, and physician and associate professor of internal medicine, Jeff Budd. The panelists focus on why clinical care pathways matter and drive the message that primary care plays an integral role in fighting fatty liver.
